<table id="ID112" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col span="1" width="34%"></col>
<col span="1" width="33%"></col>
<col span="1" width="33%"></col>
<tbody>
<tr>
<td>
<content stylecode="bold">Concomitant </content>
<content stylecode="bold">Drug</content>
<content stylecode="bold">
<br/>
</content>
</td>
<td>
<content stylecode="bold">Effect </content>
<content stylecode="bold">on </content>
<content stylecode="bold">Concentration </content>
<content stylecode="bold">of </content>
<content stylecode="bold">Lamotrigine </content>
<content stylecode="bold">or </content>
<content stylecode="bold">
<br/>
</content>
<content stylecode="bold">Concomitant </content>
<content stylecode="bold">Drug</content>
<content stylecode="bold">
<br/>
</content>
</td>
<td>
<content stylecode="bold">Clinical </content>
<content stylecode="bold">Comment </content>
<content stylecode="bold">
<br/>
</content>
</td>
</tr>
<tr>
<td>Estrogen-containing oral <br/>contraceptive preparations <br/>containing 30 mcg ethinylestradiol <br/>and 150 mcg levonorgestrel<br/>
</td>
<td>↓ lamotrigine<br/>
<br/>
<br/>
<br/>
<br/>
</td>
<td>Decreased lamotrigine levels <br/>approximately 50%.<br/>
<br/>
<br/>
<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>↓ levonorgestrel<br/>
</td>
<td>Decrease in levonorgestrel component by 19%.<br/>
</td>
</tr>
<tr>
<td>Carbamazepine (CBZ) and <br/>CBZ epoxide<br/>
</td>
<td>↓ lamotrigine<br/>
<br/>
</td>
<td>Addition of carbamazepine decreases lamotrigine <br/>concentration approximately 40%.<br/>
<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>? CBZ epoxide<br/>
</td>
<td>May increase CBZ epoxide levels<br/>
</td>
</tr>
<tr>
<td>Phenobarbital/Primidone<br/>
</td>
<td>↓ lamotrigine<br/>
</td>
<td>Decreased lamotrigine <br/>concentration approximately 40%.<br/>
</td>
</tr>
<tr>
<td>Phenytoin (PHT)<br/>
</td>
<td>↓ lamotrigine<br/>
</td>
<td>Decreased lamotrigine <br/>concentration approximately 40%<br/>
</td>
</tr>
<tr>
<td>Rifampin<br/>
</td>
<td>↓ lamotrigine<br/>
</td>
<td>Decreased lamotrigine AUC <br/>approximately 40%<br/>
</td>
</tr>
<tr>
<td>Valproate<br/>
</td>
<td>↑ lamotrigine<br/>
<br/>
</td>
<td>Increased lamotrigine concentrations slightly <br/>more than 2-fold.<br/>
<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>? valproate<br/>
</td>
<td>Decreased valproate concentrations an average of <br/>25% over a 3-week period then stabilized in healthy volunteers; <br/>no change in controlled clinical trials in epilepsy patients.<br/>
<br/>
</td>
</tr>
</tbody>
</table>